Clinical Cancer Research Meeting Calendar Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yanagawa, N.
Right arrow Articles by Motoyama, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanagawa, N.
Right arrow Articles by Motoyama, T.
Clinical Cancer Research Vol. 10, 2447-2451, April 2004
© 2004 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Demethylation of the Synuclein {gamma} Gene CpG Island in Primary Gastric Cancers and Gastric Cancer Cell Lines

Naoki Yanagawa1, Gen Tamura1, Teiichiro Honda1, Makoto Endoh1, Satoshi Nishizuka2 and Teiichi Motoyama1

1 Department of Pathology, Yamagata University School of Medicine, Yamagata, Japan, and 2 Laboratory of Molecular Pharmacology, National Cancer Institute, NIH, Bethesda, Maryland


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: Whereas synuclein {gamma} (SNCG) gene expression is usually highly tissue-specific and restricted to the nervous system, SNCG is expressed in advanced-stage breast and ovarian cancers. When overexpressed, SNCG stimulates cancer cell proliferation and metastasis. It is thought that the molecular mechanism of CpG island demethylation may underlie aberrant SNCG expression. To determine whether aberrant SNCG expression and demethylation play a role in gastric carcinogenesis, we examined the expression and methylation status of SNCG in primary gastric cancers, gastric cancer cell lines, and non-neoplastic gastric mucosal tissues.

Experimental Design: Ten gastric cancer cell lines, 105 primary gastric cancers, and 10 non-neoplastic gastric mucosal tissues were examined. SNCG expression and methylation status were examined by reverse transcription-PCR and bisulfite-single-strand conformational polymorphism followed by direct sequencing, respectively. The relationship between SNCG methylation status and various clinicopathological factors of the primary gastric cancers was then analyzed.

Results: SNCG mRNA expression was observed in 5 of 10 cell lines. Analysis of cell lines positive for SNCG expression revealed that most of the SNCG CpGs were demethylated. SNCG mRNA was not expressed in the 10 non-neoplastic gastric mucosal tissues, although several CpGs were demethylated. Of the 105 primary gastric cancers, 40 (38.1%) showed apparent SNCG demethylation, similar to the result obtained using cell lines. SNCG demethylation was more frequent in primary gastric cancers positive for lymph node metastasis (51%; 26 of 51) than in cancers without lymph node involvement (26%; 14 of 54; P < 0.05), and also more common in stage II-IV (48%; 27 of 56) than in stage I (27%; 13 of 49) cancers (P < 0.05).

Conclusions: Aberrant SNCG gene expression can occur via CpG island demethylation, and tends to occur during the more progressive stages of gastric carcinogenesis.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
DNA methylation at CpG dinucleotides has been recognized as an important mechanism for the regulation of gene expression in mammalian cells (1 , 2) . Epigenetic alterations, including hypermethylation of promoter CpG islands, histone deacetylation of tumor suppressor and tumor-related genes (1, 2, 3, 4, 5) , and global DNA hypomethylation (6, 7, 8) , have been recognized as important contributors to carcinogenesis in humans. Global DNA hypomethylation has been observed in carcinomas of the breast, liver, and colon, and is thought to occur during the early stages of tumor development (9, 10, 11, 12, 13) . However, little is known about hypomethylation of specific gene promoters, such as promoters for oncogenes and growth-related genes, with the exception of the correlation between demethylation and increased expression of c-abl, c-myc, c-Ha-ras, and raf (14, 15, 16, 17) .

The synuclein {gamma} (SNCG) gene, also known as the breast cancer specific gene 1 (BCSG1), is a member of the synuclein neuronal protein family along with synuclein {alpha} (SNCA) and synuclein ß (SNCB; Refs. 18, 19, 20 ). Although the function of synuclein proteins remains largely unknown, SNCA aggregation may be important in the etiology and pathogenesis of neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease (21) . SNCG is located on chromosome 10q23, transcribed as a 1Kb mRNA, and encodes a 127-amino acid polypeptide (19) . SNCG protein is highly tissue-specific, and is expressed at presynaptic terminals in the brain and peripheral nervous system (19 , 20) . However, this tissue specificity appears to be lost during breast and ovarian cancer disease progression. Whereas SNCG expression is normally silent in the breast and ovary, it becomes abundantly expressed in the vast majority of advanced-stage breast and ovarian cancers (22) . SNCG expression is activated by demethylation of the SNCG CpG island in a similar manner to the oncogenes and growth-related genes described above (14, 15, 16, 17 , 22) . These findings suggest that SNCG might act as a proto-oncogene, and play a positive role in the process of invasion and metastasis in breast and ovarian cancer (22) . To determine whether aberrant expression and demethylation of SNCG is involved in gastric carcinogenesis, we examined the expression and methylation status of SNCG in primary gastric cancers, gastric cancer cell lines, and non-neoplastic gastric mucosal tissues.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines.
Ten gastric cancer cell lines with different histologies were cultured under appropriate conditions in our laboratory, MKN1, an adenosquamous cell carcinoma; MKN7, a well-differentiated adenocarcinoma; MKN28 and MKN74, moderately differentiated adenocarcinomas; MKN 45 and KWS-I, poorly differentiated adenocarcinomas; KATO-III, a signet ring cell carcinoma; ECC10 and ECC12, endocrine cell carcinomas; and TSG11, a hepatoid carcinoma. Genomic DNA and mRNA were extracted from each cell line using standard procedures.

Gastric Cancer Patients and Surgical Specimens.
One hundred and five gastric cancer samples were obtained at surgery. Patients ranged in age from 43 to 89 years (mean, 67 years). All of the patients received a median of 37.5 months of follow-up care (range, 3–77 months). All of the samples were snap-frozen and stored at –80°C until processing. The tumors consisted of 40 early and 65 advanced tumors, and were identified as 69 differentiated and 36 undifferentiated tumor samples. Lymph node metastasis was positive in 51 cases, and 49 cases were stage I (Table 1)Citation . Genomic DNA was extracted from each sample using standard procedures.


View this table:
[in this window]
[in a new window]

  		Table 1 Correlation between methylation status and clinicopathological factors of primary gastric cancers

 
Non-Neoplastic Gastric Mucosal Tissues.
Ten non-neoplastic gastric mucosal tissues were obtained at autopsy. The autopsy specimens consisted of 6 males and 4 females, ranging in age from 8 to 86 years (mean, 62.7 years). Genomic DNA and mRNA were extracted from the tissues using standard procedures.

Reverse Transcription-PCR.
RNA isolated from cell lines and non-neoplastic gastric mucosal tissues was reverse transcribed and amplified using the ONE-STEP reverse transcription-PCR System (Life Technologies, Inc., Gaithersburg, MD). Primer sequences used were sense 5'-CAA GAA GGG CTT CTC CAT CGC CAA GG-3' and antisense 5'-CCT CTT TCT CTT TGG ATG CCA CAC CC-3' for SNCG (318 bp; Ref. 22 ). A 587-bp ß-actin fragment was amplified as a control. After initial activation of the enzyme at 94°C for 2 min, PCR reactions were exposed to 38 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s.

5-Aza-2'-Deoxycytidine Treatment.
To examine SNCG expression in response to treatment with 5-aza-2'-deoxycytidine (Sigma), cell lines were incubated for 96 h with 0.2 or 1 µM 5-aza-2'-deoxycytidine, and then harvested for RNA extraction and reverse transcription-PCR.

Bisulfite-Single-Strand Conformation Polymorphism (SSCP) and Sequencing Analyses.
DNA samples were treated with bisulfite to convert all of the unmethylated cytosines to uracils, while leaving methylated cytosines unaffected. Briefly, 2 µg of aliquots of genomic DNA were denatured by treatment with NaOH and modified by sodium bisulfite. DNA samples were then purified using Wizard DNA purification resin (Promega, Madison, WI), treated with NaOH, precipitated with ethanol, and resuspended in 30 µl. DNA methylation status was determined by bisulfite-SSCP with some modifications (23) . After treatment of DNA with sodium bisulfite, a 415-bp fragment encompassing the CpG island, and exon 1 of the SNCG gene was amplified using primers 5'-GGT TGA GTT AGT AGG AGT TTA-3' and 5'-CCT ACC ATA CCC CAC TTA CCC-3' (22) . The PCR mix contained 1x PCR buffer [15 mM Tris-HCl (pH 8.0) and 50 mM KCl], 1.5 mM MgCl2, 1 µM each primer, 0.2 mM deoxynucleoside triphosphates, 0.5 units of Taq polymerase (AmpliTag Gold DNA Polymerase; PE Applied Biosystems, Foster City, CA), 5% DMSO, and 2.5 µCi [{alpha}-32P]dCTP (Amersham, Buckinghamshire, England), and genomic DNA (100 ng) in a final volume of 10 µl. After activation of the Taq polymerase at 95°C for 10 min, PCR was performed in a GeneAmp PCR System 9700 (PE Applied Biosystems) for 38 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 45 s, and extension at 72°C for 60 s, followed by a final 7 min extension at 72°C. PCR products were diluted 1:10 in denaturing loading buffer [95% formamide, 10 mM EDTA (pH 8.0), 0.02% xylene cyanol FF, and 0.02% bromphenol blue], heated at 95°C for 4 min, placed on ice, and 2 µl aliquots subjected to electrophoresis on 6% polyacrylamide gels. Gels were dried and exposed to hyperfilm MP autoradiography film (Amersham) for 4–16 h. Direct sequencing was performed using small pieces of the gel containing the shifted band detected by bisulfite-SSCP. Gel slices were immersed in 50 µl of water, heated to 95°C, and then applied to PCR under the conditions described above for SSCP, except that PCR was carried out in a volume of 50 µl. The PCR products were then purified using the QIA quick PCR purification kit (Qiagen, Tokyo, Japan) and sequenced using the Big Dye Terminator Cycle Sequencing Ready Reaction kit (PE Applied Biosystems). Gel electrophoresis, data collection, and analysis were performed on a Genetic Analyzer (model 310; PE Applied Biosystems).

Statistical Analysis.
Statistical comparisons were performed using Student’s t test, Fisher’s exact test, or {chi}2 test, as appropriate. Ps < 0.05 were considered statistically significant. Kaplan-Meier analysis was performed to estimate a survival function over time for individual covariates. Survival estimates between cancers exhibiting SNCG methylation or demethylation were compared by log-rank test.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
mRNA Expression and Methylation Status of SNCG in Gastric Cancer Cell Lines.
SNCG mRNA was observed in 5 of the 10 cell lines (MKN28, MKN74, KATO-III, KWS-I, and ECC12; Fig. 1Citation ). The SNCG mRNA-expressing cell lines all exhibited mobility-shifted bands by bisulfite-SSCP (Fig. 2A)Citation . Sequencing of the SSCP bands revealed that whereas the SNCG exon 1 CpGs were mostly demethylated in the cell lines positive for SNCG mRNA (Fig. 3A)Citation , the CpGs remained methylated in the remaining 5 cell lines (Fig. 3B)Citation , and the latter cell lines expressed SNCG mRNA after 5-aza-2'-deoxycytidine treatment (Fig. 4)Citation .



View larger version (46K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Reverse transcription-PCR results from 10 gastric cancer cell lines. SNCG reverse transcription-PCR product (318 bp) is present in Lanes 3, 5, 6, 7 and 10. ß-actin (587 bp) serves as an internal control. Lanes 1, MKN1; 2, MKN7; 3, MKN28; 4, MKN45; 5, MKN74; 6, KATO-III; 7, TSG11; 8, KWS-I; 9, ECC10; and 10, ECC12. SM, size marker.

 


View larger version (85K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Bisulfite-single-strand conformation polymorphism of gastric cancer cell lines (A) and primary gastric cancers (B). A, mobility shifts are seen in Lanes 3, 5, 6, 7, and 10 (arrowhead). Lanes 1, MKN1; 2, MKN7; 3, MKN28; 4, MKN45; 5, MKN74; 6, KATO-III; 7, TSG11; 8, KWS-I; 9, ECC10; and 10, ECC12. B, mobility shifts are observed for M135 and M171 (arrowhead).

 


View larger version (86K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Sequencing histograms of SNCG exons 1 using an antisense primer. Bisulfite treatment of the MKN 74 DNA converted all cytosines to thymines (A), cytosines remained as cytosines in TSG11 (B). Several cytosines were converted to thymines and others remained as cytosines in a non-neoplastic gastric mucosal tissue obtained at autopsy (C). *, converted thymines.

 


View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Comparison of SNCG mRNA expression before (–) and after (+) 5 aza-dC treatment. Treatment with 5 aza-dC restored SNCG mRNA expression in MKN1 and MKN7, but did not affect SNCG expression level in MKN28.

 
Methylation Status in Primary Gastric Cancers.
Of the 105 primary gastric cancer samples examined, 40 (38.1%) showed band mobility shifts by SSCP. Sequencing of the shifted bands demonstrated demethylated CpGs, similar to the results obtained for the gastric cancer cell lines that expressed SNCG mRNA (Fig. 2B)Citation .

mRNA Expression and Methylation Status of SNCG in Non-Neoplastic Gastric Mucosal Tissues.
SNCG mRNA was not expressed in any of the 10 non-neoplastic gastric mucosal tissues. However, a few tissues exhibited faint bands with mobility shifts by bisulfite-SSCP (data not shown), and sequencing of these bands revealed partial demethylation of SNCG CpGs (Fig. 3C)Citation .

Correlation between Methylation Status and Clinicopathological Factors of Primary Gastric Cancers.
Clinicopathological features of primary gastric cancers showing SNCG demethylation were analyzed. Demethylation of SNCG was more frequent in lymph node metastasis-positive primary gastric cancers (51%; 26 of 51) than in metastasis-negative cancers (26%; 14 of 54; P < 0.05), and in stage II-IV cancers (48%; 27 of 56) than in stage I cancers (27%; 13 of 49; P < 0.05; Table 1Citation ).

SNCG Demethylation and Patient Prognosis.
Kaplan-Meier estimates were used to examine the relationship between SNCG demethylation and patient survival. Although not statistically significant, there was a tendency toward patients with a poor prognosis showing SNCG demethylation (P = 0.076; Fig. 5Citation ).



View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Overall survival of 105 gastric cancer patients. There was a tendency for patients with poor prognosis to show SNCG demethylation compared with patients with normal methylation (P = 0.076).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we examined the expression and/or methylation status of SNCG in gastric cancer cell lines, primary gastric cancers, and non-neoplastic gastric mucosal tissues. For the gastric cancer cell lines, SNCG mRNA expression strongly correlated with demethylation of SNCG exon 1 CpG islands. Whereas SNCG was not expressed in non-neoplastic gastric mucosal tissues obtained at autopsy, partial demethylation was present in these tissues. We also examined SNCG methylation status in several non-neoplastic gastric mucosal tissues from gastric cancer patients. Although demethylation of SNCG was observed frequently in these tissues, demethylation only affected a few CpGs, similar to the autopsy samples (data not shown). Similar findings have also been reported for normal breast tissue (22) . These results suggest that demethylation occurs before malignant transformation and that only partial demethylation does not result in up-regulated SNCG mRNA expression. Thus, it appears that partial SNCG demethylation can occur in normal gastric mucosa, which then extends in some cases to become to fully demethylated, resulting in up-regulated SNCG mRNA expression. At present, the normal cellular functions of SNCG are largely unknown. Future studies are required to clearly define the function of this protein in neurons as well as in neoplasms, and will provide insight into the molecular mechanisms that contribute to human carcinogenesis.

We also analyzed the clinicopathological features of gastric cancers that showed SNCG demethylation. Previous studies have suggested that SNCG acts as an oncogene in breast and ovarian cancer cells (22 , 24 , 25) . A stage-specific expression pattern of SNCG mRNA has been demonstrated by in situ hybridization that varied from virtually no detectable expression in normal or benign breast tissues to low level or partial expression in low-grade ductal carcinoma in situ, through to high expression in advanced infiltrating carcinomas (24) . Similarly, immunohistochemical studies have shown that SNCG protein is not expressed in normal breast tissues but is expressed in a high percentage of stage III/IV breast carcinomas (25) . SNCG is also expressed in ovarian cancers (25) . In the present study, SNCG demethylation was more frequent in primary gastric cancers positive for lymph node metastasis (51%; 26 of 51) than in metastasis-negative cancers (26%; 14 of 54; P < 0.05), and was also more frequent in stage II-IV cancers (48%; 27 of 56) than in stage I cancers (27%; 13 of 49; P < 0.05). Our results are in agreement with those obtained for breast and ovarian cancers (25) . Although not statistically significant, there was an increased tendency for gastric cancer patients with poor prognoses to show SNCG demethylation compared with gastric cancer patients with normal methylation (P = 0.076).

Although additional studies on gene methylation, protein expression, and localization in normal and transformed tissues are required to establish that the methylation status of synuclein {gamma} CpG islands regulates mRNA, and ultimately protein expression, a distinct correlation between mRNA levels and CpG methylation is established by the present study. Our study indicated that SNCG was frequently expressed, via CpG demethylation, during the more progressive stages of gastric carcinogenesis. SNCG, a potential oncoprotein, may play a role in the progression and metastasis of common human malignancies.



View larger version (2K):
[in this window]
[in a new window]
[Download PPT slide]
 
 

   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Gen Tamura, Department of Pathology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan. Phone: 81-23-628-5243; Fax: 81-23-628-5245; E-mail: gtamura{at}med.id.yamagata-u.ac.jp

Received 8/28/03; revised 12/18/03; accepted 1/ 2/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet, 3: 415-28, 2002.[Medline]
  2. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science, 293: 1068-70, 2001.[Abstract/Free Full Text]
  3. Goodman JI, Watson RE. Altered DNA methylation: a secondary mechanism involved in carcinogenesis. Ann Rev Pharmacol Toxicol, 42: 501-25, 2002.[CrossRef][Medline]
  4. Kim MS, Kwon HJ, Lee YM, et al Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med, 7: 437-43, 2001.[CrossRef][Medline]
  5. Choi JH, Kwon HJ, Yoon BI, et al Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res, 92: 1300-4, 2001.[CrossRef][Medline]
  6. Lengauer C. An unstable liaison. Science, 300: 442-3, 2003.[Abstract/Free Full Text]
  7. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science, 300: 455 2003.[Free Full Text]
  8. Gaudet F, Hodgson JG, Eden A, et al Induction of tumors in mice by genomic hypomethylation. Science, 300: 489-92, 2003.[Abstract/Free Full Text]
  9. Narayan A, Ji W, Zhang XY, et al Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer, 77: 833-8, 1998.[CrossRef][Medline]
  10. Lin CH, Hsieh SY, Sheen IS, et al Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res, 61: 4238-43, 2001.[Abstract/Free Full Text]
  11. Bariol C, Suter C, Cheong K, et al The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol, 162: 1361-71, 2003.[Abstract/Free Full Text]
  12. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasm. Science, 228: 187-90, 1985.[Abstract/Free Full Text]
  13. Cravo M, Pinto R, Fidalgo P, et al Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. Gut, 39: 434-8, 1996.[Abstract/Free Full Text]
  14. Weitzman SA, Lee RM, Ouellette AJ. Alteration in c-abl gene m ethylation in cells transformed by phagocyte-generated oxidants. Biochem Biophys Res Comm, 158: 24-30, 1989.[CrossRef][Medline]
  15. Cheah MS, Wallace CD, Hoffman RM. Hypomethylation of DNA in human cancer cells: a site-specific change in the c-myc oncogene. J Natl Cancer Inst, 73: 1057-65, 1984.
  16. Sharrard RM, Royds JA, Rogers S, Shorthouse AJ. Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer, 65: 667-72, 1992.[Medline]
  17. Counts JL, Goodman JI. Hypomethylation of DNA: an epigenetic mechanism involved in tumor promotion. Mol Carcinog, 11: 185-8, 1994.[Medline]
  18. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett, 345: 27-32, 1994.[CrossRef][Medline]
  19. Lavedan C, Leroy E, Dehejia A, et al Identification, localization and characterization of the human {gamma}-synuclein gene. Hum Genet, 103: 106-12, 1998.[CrossRef][Medline]
  20. Ninkina N, Alimova-Kost M, Paterson J, et al Organization, expression and polymorphism of the human persyn gene. Hum Mol Genet, 7: 1417-24, 1998.[Abstract/Free Full Text]
  21. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. Abnormal accumulation of NACP/{alpha}-synuclein in neurodegenerative disorders. Am J Pathol, 152: 367-72, 1998.[Abstract]
  22. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res, 63: 664-73, 2003.[Abstract/Free Full Text]
  23. Suzuki H, Itoh F, Toyota M, et al Quantitative DNA methylation analysis by fluorescent polymerase chain reaction single-strand conformation polymorphism using an automated DNA sequencer. Electrophoresis, 21: 904-8, 2000.[CrossRef][Medline]
  24. Ji H, Liu YE, Jia T, et al Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res, 57: 759-64, 1997.[Abstract/Free Full Text]
  25. Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer, 88: 2154-63, 2000.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. Hibi, T. Mori, M. Fukuma, K. Yamazaki, A. Hashiguchi, T. Yamada, M. Tanabe, K. Aiura, T. Kawakami, A. Ogiwara, et al.
Synuclein-{gamma} Is Closely Involved in Perineural Invasion and Distant Metastasis in Mouse Models and Is a Novel Prognostic Factor in Pancreatic Cancer
Clin. Cancer Res., April 15, 2009; 15(8): 2864 - 2871.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. Ahmad, S. Attoub, M. N. Singh, F. L. Martin, and O. M. A. El-Agnaf
{gamma}-Synuclein and the progression of cancer
FASEB J, November 1, 2007; 21(13): 3419 - 3430.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Y. Nakamura, F. Tanaka, H. Nagahara, K. Ieta, N. Haraguchi, K. Mimori, A. Sasaki, H. Inoue, K. Yanaga, and M. Mori
Opa Interacting Protein 5 (OIP5) Is a Novel Cancer-testis Specific Gene in Gastric Cancer
Ann. Surg. Oncol., February 1, 2007; 14(2): 885 - 892.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Liu, W. Liu, Y. Wu, Y. Zhou, R. Xue, C. Luo, L. Wang, W. Zhao, J.-D. Jiang, and J. Liu
Loss of Epigenetic Control of Synuclein-{gamma} Gene as a Molecular Indicator of Metastasis in a Wide Range of Human Cancers
Cancer Res., September 1, 2005; 65(17): 7635 - 7643.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yanagawa, N.
Right arrow Articles by Motoyama, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanagawa, N.
Right arrow Articles by Motoyama, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online